Medtronic announced third-quarter financial results on Tuesday. Here are three things to know: 

Building momentum 
We continued to deliver mid-single digit revenue growth thanks to the strong performance of businesses companywide. Our U.S. Diabetes business returned to growth with help from MiniMed™ 780G. And many other businesses, including Core Spine, Cardiac Surgery, and Structural Heart were notably strong. 

Innovation-driven future 
Many of our promising therapies received key regulatory approvals in the past two quarters. And that innovation will be reflected in future earnings. Major products moving through our pipeline include Aurora EV-ICD™, PulseSelect™, Percept™ RC, Simplera Sync™, and the Symplicity™ procedure for hypertension.   

A boost to guidance  
Based on our year-to-date performance – including this quarter – we are raising our full-year guidance on both the top and bottom line.  

L009-02192024

Related content

Five healthcare technology trends in 2024

Astonishing teamwork drove renal denervation at Medtronic

Upfront tuition coverage is a game-changer for Medtronic employees